Pelogen.comA PANACEA BIO CHEM RESEARCH PLATFORMAn independent Panacea Bio Chem research platform
MENU

Investigational Research Platform — Not Approved for Therapeutic Use

PP405 HAIR REGROWTH RESEARCH

PP405 Hair Regrowth Research Serum

Pelogen™ — Follicular Reactivation Research Serum

Pelogen™ is an independent Panacea Bio Chem topical formulation platform developed for the laboratory study of PP405, dormant hair follicles, follicular stem-cell metabolism and androgenetic alopecia.

Investigational research platform. Not an approved hair-loss treatment.

PP405 is an investigational topical small molecule originated outside Panacea Bio Chem. Pelogen™ studies formulation questions around this compound class in the laboratory only.

PP405 Pelogen Hair regrowth serum by Panacea100 mL
PP405 Pelogen Hair regrowth serum by Panacea

FOR LABORATORY AND FORMULATION RESEARCH PURPOSES ONLY.NOT FOR HUMAN OR VETERINARY USE.NOT AN APPROVED MEDICINE, MEDICAL DEVICE OR CONSUMER COSMETIC PRODUCT.

RESEARCH USE ONLY

FOR LABORATORY AND FORMULATION RESEARCH PURPOSES ONLY.NOT FOR HUMAN OR VETERINARY USE.NOT AN APPROVED MEDICINE, MEDICAL DEVICE OR CONSUMER COSMETIC PRODUCT.

THE SCIENTIFIC PREMISE

PP405 Hair Regrowth Research

PP405 hair regrowth research begins with a distinction that matters: a follicle that has been destroyed is gone, but a follicle that has miniaturised still exists — and published biology indicates that many pattern-loss follicles persist as a present-but-dormant follicular system whose stem cells remain in place.[1][10]

That distinction defines the research question. If the follicular apparatus is dormant rather than absent, then the metabolic state of its stem cells becomes a legitimate object of study — and the investigation of hair-cycle biology becomes an investigation of whether dormancy can be studied, measured and understood as a reversible biological state.[2]

Pelogen™ exists for the disciplined study of that question. It is designed for the study of follicular metabolism in the laboratory; every stronger claim belongs to evidence that does not yet exist and is not asserted here.

PP405 dormant hair follicle mechanism research illustration: a miniaturised but present follicle beside a follicle in an active hair-cycle state, with the bulge stem-cell region marked
Scientific illustration — not experimental imagery
Research model — a proposed mechanism under investigation, not an established pathway in humans

THE RESEARCH MODEL

How PP405 May Reactivate Dormant Hair Follicles

The proposed mechanism is metabolic, and it is presented here strictly as a research model. Hair-follicle stem cells are unusual among skin cells: they run glycolytically and produce lactate, and published research indicates that this metabolic state gates their activation.[2]

PP405-class compounds inhibit the mitochondrial pyruvate carrier — the gate through which pyruvate would otherwise enter mitochondria for oxidation. In the model, that inhibition diverts pyruvate toward lactate production and shifts the stem cell toward the activation-prone state, opening the investigation of a transition from dormancy toward an active hair-cycle state.[3]

No guaranteed-regrowth depiction is made or implied. The model is under third-party clinical investigation and requires further clinical validation; Pelogen™ studies formulation questions around this biology in the laboratory only.

THE CELLULAR CONTEXT

PP405 and Hair-Follicle Stem-Cell Metabolism

Hair-follicle stem cells sit in the bulge region of the follicle and hold the lineage that rebuilds the hair shaft each cycle. Their behaviour is inseparable from their metabolism: published work shows these cells are markedly more glycolytic than their neighbours, and that lactate dehydrogenase activity is not a bystander but a driver of their activation.[2]

The same research programme showed that genetic deletion of the mitochondrial pyruvate carrier in mouse follicle stem cells raised lactate output and accelerated entry into the hair cycle — and that a small-molecule carrier inhibitor could do the same topically in animals.[2][3]

This is the cellular stage on which the entire PP405 research question is set. It is also the boundary of the evidence: mouse genetics and mouse pharmacology, beautifully controlled, are still mouse evidence.

Hair-follicle stem-cell reactivation research illustration: follicular cross-section with the bulge stem-cell niche highlighted and metabolic cues marking the lactate-producing glycolytic state
Scientific illustration — not experimental imagery

THE COMPOUND

What Is PP405?

PP405 is an investigational topical small molecule — a mitochondrial pyruvate-carrier inhibitor — studied by third parties for its action on hair-follicle stem-cell metabolism. In 2026 the World Health Organization INN programme published the proposed international nonproprietary name suvomipic for the compound, classing it as a mitochondrial pyruvate carrier inhibitor.[9]

Its research status is plain: PP405 is investigational, is not an approved drug anywhere, and is in clinical development by Pelage Pharmaceuticals, which licensed the University of California-originated intellectual property.[7][6]

Pelogen™ is not the originator of PP405, does not present itself as such, and studies this compound class strictly as an independent formulation-research platform.

THE CONDITION CONTEXT

PP405 Research in Androgenetic Alopecia

Androgenetic alopecia — pattern hair loss — is the condition in which third-party PP405 research is being conducted. Its biology is precisely the premise above: in pattern loss, follicles typically miniaturise and fall dormant rather than disappear, which is why a metabolic-reactivation hypothesis is scientifically interesting at all.[1]

The developer’s completed Phase 2a study enrolled 78 adults with androgenetic alopecia under a randomized, double-blind, vehicle-controlled design, and its announced Phase 3 programme targets the same condition from 2026.[4][6]

THIRD-PARTY HUMAN DATA

What Early PP405 Clinical Research Has Reported

The human evidence is early and company-reported. Pelage Pharmaceuticals states that its Phase 2a trial met the primary tolerability endpoint and the secondary pharmacokinetic endpoint, with no detectable systemic absorption of PP405 in blood.[5]

The same announcement reports an exploratory signal: at week 8, 31% of treated men with a higher degree of hair loss showed a greater than 20% increase in hair density, versus 0% on vehicle. That is a small subgroup, an early timepoint and a company communication — meaningful as a signal, decisive only after peer-reviewed publication and larger controlled evaluation.[5]

These are third-party PP405 studies conducted and reported by Pelage Pharmaceuticals. They are not Pelogen™ clinical trials, they involve no Pelogen™ formulation, and they establish nothing about Pelogen™.

THE PANACEA PROGRAMME

Pelogen™ Formulation Research Platform

Pelogen™ is Panacea Bio Chem’s independent topical formulation-research platform: an engineering investigation of the vehicle questions that any serious follicular metabolic research programme must answer long before biology enters the picture. The formulation is described only at a high level — a proprietary, pH-controlled topical research vehicle incorporating a controlled solvent system, aqueous matrix, humectant phase, solubilisation system and polymer-supported scalp interface.

Its research priorities are delivery-environment control, solvent-phase uniformity, aqueous-phase compatibility, pH control, follicular surface contact, physical stability, reproducibility, a disciplined preservation strategy, packaging protection and the minimisation of unnecessary formulation stress. No concentrations, ratios, ingredient lists or manufacturing detail are published.

Abstract architecture — no recipe, no ingredients, no composition disclosed

Platform identity

Platform
Pelogen™ — independent topical formulation-research platform
Research subject
PP405 — third-party investigational topical small molecule
Vehicle concept
Proprietary pH-controlled topical research vehicle
Vehicle architecture
Controlled solvent system · aqueous matrix · humectant phase · solubilisation system · polymer-supported scalp interface
Selection method
Dicoias Ψ computed-chemistry advisory (structure-guided descriptors)
Developer
Panacea Bio Chem
Formulation disclosure
Composition intentionally undisclosed — no concentrations, ratios or manufacturing detail published
Status
Laboratory and formulation research only — no Pelogen-specific clinical trial performed or claimed

Pelogen™ is an independent Panacea Bio Chem research vehicle — not the clinical-trial formulation and not equivalent to it.

RESEARCH USE ONLY

FOR LABORATORY AND FORMULATION RESEARCH PURPOSES ONLY.NOT FOR HUMAN OR VETERINARY USE.NOT AN APPROVED MEDICINE, MEDICAL DEVICE OR CONSUMER COSMETIC PRODUCT.

THE SELECTION METHOD

Computed-chemistry selection: the Dicoias Ψ advisory

Behind Pelogen™ excipient and stability reasoning stands the Dicoias Ψ (PSY) display-only advisory architecture — a Panacea Bio Chem research programme and engineering concept that treats formulation selection as a computed-chemistry discipline rather than a habit. Candidate excipient structures are mapped as structure-guided Λ-vectors across the formulation space, and electronic-structure descriptors — HOMO and LUMO energies and the HOMO–LUMO gap, computed at the GFN2-xTB semi-empirical quantum-chemistry level — inform compatibility and stability reasoning before laboratory work begins.

The architecture is display-only and advisory: it computes, ranks and explains, and a scientist decides. Its defining discipline is honesty at the boundary — when a descriptor cannot be computed for a structure, the system declines to advise rather than estimating beyond its ground. The method is celebrated here for what it is: a way of asking better formulation questions. It predicts no biological outcome, and none is claimed from it.

THE BOUNDARY

How Pelogen™ Differs from the Clinical-Trial Formulation

The Phase 2a trial of PP405 used the developer’s own proprietary trial formulation. Pelogen™ is not that formulation: it is an independent Panacea Bio Chem research vehicle, built for laboratory formulation research and never evaluated in any human study.[4]

No equivalence — pharmaceutical, pharmacokinetic or biological — is claimed or implied between Pelogen™ and any clinical-trial formulation. The trial results belong to the developer’s formulation and cannot be transferred to any other vehicle; formulation is part of what a trial tests.

THE EVIDENCE LADDER

The Evidence Ladder — and Where Pelogen™ Stands

Seven steps from foundational biology to this platform. Read it as a ladder of separation: third-party PP405 data occupy the middle rungs, and they are not — and cannot become — clinical validation of Pelogen™.

  1. STEP 1Foundational follicular biologyPeer-reviewed researchThe hair cycle is driven by hair-follicle stem cells whose dormancy and activation are regulated by local niche and systemic signals.
  2. STEP 2Mitochondrial metabolic researchPeer-reviewed researchPublished work shows follicle stem cells are glycolytic and that lactate production gates their activation.
  3. STEP 3Preclinical compound investigationPreclinical evidenceIn mouse models, inhibiting mitochondrial pyruvate entry stimulated the hair cycle, including in alopecia-model systems.
  4. STEP 4Early human tolerability and target-engagement researchCompany-reported clinical dataThe developer reports Phase 2a tolerability and pharmacokinetic endpoints were met, with no detectable systemic absorption — company-reported, not peer-reviewed.
  5. STEP 5Controlled clinical evaluationClinical registryLarger controlled evaluation (Phase 3) is announced by the developer from 2026; it has not yet reported.
  6. STEP 6Independent validation still requiredNot independently clinically verifiedNo independent, peer-reviewed replication of the human PP405 findings exists at the last evidence search.
  7. STEP 7Pelogen formulation researchPelogen formulation researchPanacea Bio Chem’s own contribution sits here: laboratory vehicle research. It inherits nothing from the steps above except scientific context.

RESEARCH STATUS AND REGULATORY LIMITATIONS

PP405 Research Status and Regulatory Limitations

PELOGEN STATUS

  • Independent formulation-research platform
  • PP405-based research concept
  • Laboratory and formulation research only
  • No therapeutic approval
  • No consumer-use authorisation
  • No claim of equivalence to a clinical-trial formulation
  • No completed Pelogen-specific clinical trial
  • Further analytical, stability and biological validation required

PP405 itself is investigational and unapproved everywhere; the developer’s Phase 3 programme is announced from 2026 and has not reported. Pelogen™ adds no clinical claim of any kind on top of that record.[6]

RESEARCH WATCH

Last updated: 2026-08-04

  • 2025-06-17

    Pelage Pharmaceuticals reports positive Phase 2a topline results for topical PP405 in androgenetic alopecia

    Company-reported clinical data

    The third-party compound whose follicular stem-cell mechanism Pelogen™ vehicle research studies. The developer reports the primary tolerability endpoint and secondary pharmacokinetic endpoint were met with no detectable systemic absorption, and an exploratory signal: at week 8, 31% of treated men with a higher degree of hair loss showed a greater than 20% density increase versus 0% on vehicle. Company-reported, not peer-reviewed — and not Pelogen™ data.

    Company-reported

    Pelage Pharmaceuticals press release

  • 2024-06-05

    NCT06393452: randomized, double-blind, vehicle-controlled Phase 2a study of topical PP405 in adults with androgenetic alopecia — 78 subjects, completed

    Clinical registry

    The authoritative registration record behind every third-party clinical statement on this site. Registry records document design and status, not results; this is the developer’s trial of its own compound and contains no Pelogen™ research.

    Registered

    ClinicalTrials.gov (US National Library of Medicine)

  • 2025-10-15

    Pelage Pharmaceuticals announces $120M Series B financing to advance PP405 into Phase 3 trials from 2026

    Company announcement

    Signals that the decisive controlled evaluation of the third-party compound is still ahead: Phase 3 is funded and planned from 2026, not reported. Context for the Pelogen™ research watch — third-party financing news, not a Pelogen™ milestone.

    Company-reported

    Pelage Pharmaceuticals press release

  • 2017-08-14

    Flores et al., Nature Cell Biology: lactate dehydrogenase activity drives hair-follicle stem-cell activation

    Peer-reviewed research

    The mechanistic foundation for the whole research field: follicle stem cells are glycolytic, lactate production gates their activation, and mitochondrial pyruvate-carrier inhibition accelerated the hair cycle in mice. Mechanistic context for the research platform — animal and cellular evidence, not human data.

    Published

    Nature Cell Biology via PubMed

  • 2021-03-19

    Experimental Dermatology: inhibition of pyruvate oxidation stimulates the hair cycle in models of alopecia

    Peer-reviewed research

    Preclinical extension of the metabolic pathway: blocking pyruvate entry into mitochondria accelerated the hair cycle in mouse alopecia models driven by age, chemotherapy and stress. Frames follicular pyruvate handling as a research target — animal-model evidence only.

    Published

    Experimental Dermatology via PubMed

  • 2019-01-03

    WO2019006359A1: UC Regents patent — compositions and methods for modulating hair growth via mitochondrial pyruvate-carrier inhibition

    Patent literature

    Documents that the PP405 compound class is third-party University of California-originated intellectual property — the origin record that Pelogen™ acknowledges and does not imitate. Patent literature is an invention record, not clinical evidence.

    Published

    Google Patents (WIPO publication)

  • 2026-09-01

    Discovery and evaluation of SIPI11594: a novel mitochondrial pyruvate carrier inhibitor with anti-hair loss efficacy

    PP405 & follicle metabolism watch

    1. Bioorg Med Chem. 2026 Sep;140:118715. doi: 10.1016/j.bmc.2026.118715. Epub 2026 May 28. Discovery and evaluation of SIPI11594: a novel mitochondrial pyruvate carrier inhibitor with anti-hair loss efficacy. Zhang H(1), Wu X(2), Huang Y(1), Peng X(3), Han B(1), Li M(3), Zhang Q(4).

    Peer-reviewed study

    Bioorganic & medicinal chemistry via PubMed

  • 2026-07-14

    Melatonin Promotes Human Hair Follicle Stem Cell Proliferation by Suppressing 5-AR: Implications for Treating Androgenetic Alopecia

    PP405 & follicle metabolism watch

    1. J Craniofac Surg. 2026 Jul 14. doi: 10.1097/SCS.0000000000013135. Online ahead of print. Melatonin Promotes Human Hair Follicle Stem Cell Proliferation by Suppressing 5-AR: Implications for Treating Androgenetic Alopecia. He P(1), Wei W(2), Ye Y(3), Hu P(2)(4), Xie Y(2).

    Peer-reviewed study

    The Journal of craniofacial surgery via PubMed

  • 2026-07-01

    Emerging pharmacotherapies for androgenetic alopecia

    PP405 & follicle metabolism watch

    1. Expert Opin Pharmacother. 2026 Jul;27(10):929-939. doi: 10.1080/14656566.2026.2690108. Epub 2026 Jun 17. Emerging pharmacotherapies for androgenetic alopecia. Agrawal A(1), Dreifus EM(2), Tosti A(2). Author information: (1)Department of Dermatology, All India Institute of Medical Sciences, Bhopal, India. (2)Dr.

    Peer-reviewed review

    Expert opinion on pharmacotherapy via PubMed

  • 2026-06-03

    Development and validation of a comprehensive in vitro organ model for androgenetic alopecia

    PP405 & follicle metabolism watch

    1. BMC Biotechnol. 2026 Jun 3;26(1):76. doi: 10.1186/s12896-026-01176-4. Development and validation of a comprehensive in vitro organ model for androgenetic alopecia. Liu S(1), Li W(1), Jiang B(1), Li H(1), Chen J(1), Fan Z(1), Hu Z(2), Qu Q(3), Miao Y(4).

    Peer-reviewed study

    BMC biotechnology via PubMed

THE EVIDENCE BASE

Scientific Source Library

Every factual claim on this site traces to one of these records. Each entry shows its evidence category, publication date, what it supports and what it does not show. Citation markers like [2] throughout the site link here.

Last scientifically reviewed: 2 August 2026

Foundational follicular biology

[1]Peer-reviewed research2011

Dynamics between stem cells, niche, and progeny in the hair follicle

Hsu YC, Pasolli HA, Fuchs E. · Cell, 144(1):92-105 · 2011

Original source ↗ · doi:10.1016/j.cell.2010.11.049 · PMID 21215372

What it supports
Foundational follicular biology: how hair-follicle stem cells, their niche and their progeny coordinate the hair cycle — the framework within which follicular dormancy and activation are defined.
What it does not show
Reviews follicle biology generally; it predates and does not address metabolic modulation of the hair cycle or any specific compound.

Mitochondrial pyruvate-carrier research

[3]Preclinical evidence2021

Inhibition of pyruvate oxidation as a versatile stimulator of the hair cycle in models of alopecia

Flores A, et al. · Exp Dermatol, 30(4):448-456 · 2021

Original source ↗ · doi:10.1111/exd.14307 · PMID 33739490

What it supports
Extends the MPC pathway: inhibiting pyruvate entry into mitochondria accelerated the hair cycle in mouse models of alopecia driven by age, repeated chemotherapy and stress, with histologically normal follicles forming within 30-40 days of treatment in those models.
What it does not show
Preclinical animal-model work; the authors themselves frame human use as a proposal. No human alopecia data; no long-term human outcome data.

Relevance to Pelogen™ · Preclinical context for why follicular pyruvate handling is a research-worthy target — it is not human evidence and not Pelogen™ data.

Hair-follicle stem-cell research

[2]Peer-reviewed research2017

Lactate dehydrogenase activity drives hair follicle stem cell activation

Flores A, et al. · Nat Cell Biol, 19(9):1017-1026 · 2017

Original source ↗ · doi:10.1038/ncb3575 · PMID 28812580

What it supports
The mechanistic anchor: hair-follicle stem cells are glycolytic, lactate generation is required for their activation, and deleting or pharmacologically inhibiting the mitochondrial pyruvate carrier (Mpc1) in mice increased lactate production and accelerated HFSC activation and the hair cycle.
What it does not show
Mouse genetics and topical small-molecule experiments in animals; it does not establish that the same metabolic intervention activates human follicles or restores hair in people.

Relevance to Pelogen™ · The published biological basis for studying follicular stem-cell metabolism — mechanistic context for the Pelogen™ research platform, not evidence about Pelogen™.

PP405 clinical registry

[4]Clinical registry2024

A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia (NCT06393452)

ClinicalTrials.gov, US National Library of Medicine. Sponsor: Pelage Pharmaceuticals, Inc. · Registry record — study started 2024-06-05; status: completed · 2024

Original source ↗

What it supports
Authoritative registration record for the third-party PP405 Phase 2a trial: randomized, double-blind, vehicle-controlled design in 78 adults with androgenetic alopecia, sponsored by Pelage Pharmaceuticals.
What it does not show
A registry entry documents design and status, not peer-reviewed results. It is a record about the developer’s compound — it contains no Pelogen™ research.

Relevance to Pelogen™ · The registry anchor for all third-party clinical statements on this site — a third-party compound that Pelogen™ vehicle research studies, reported as registry fact.

Official PP405 developer communications

[5]Company-reported clinical data2025

Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy

Pelage Pharmaceuticals, Inc. (press release) · Company announcement, 2025-06-17 · 2025

Original source ↗

What it supports
Company-reported Phase 2a topline: the sponsor states the trial met its primary tolerability endpoint and secondary pharmacokinetic endpoint with no detectable systemic absorption of PP405 in blood, and reports an exploratory signal — at week 8, 31% of treated men with a higher degree of hair loss showed a greater than 20% increase in hair density versus 0% on vehicle.
What it does not show
Company-reported, not peer-reviewed; a small exploratory subgroup at an early timepoint; not an independent replication and not an approved indication. These are third-party data about PP405 — not Pelogen™ data, and not evidence of any Pelogen™ effect.

Relevance to Pelogen™ · Reported here at full label: third-party company-reported clinical data describing the compound Pelogen™ vehicle research studies — never presented as Pelogen™ results.

[6]Company-reported clinical data2025

Pelage Pharmaceuticals Announces $120 Million Series B Financing to Advance Regenerative Medicine Treatments for Hair Loss

Pelage Pharmaceuticals, Inc. (press release) · Company announcement, 2025-10-15 · 2025

Original source ↗

What it supports
Company announcement of a $120M Series B financing (co-led by ARCH Venture Partners and GV) intended to fund advancement of PP405 into Phase 3 trials from 2026, restating the Phase 2a tolerability and exploratory density observations.
What it does not show
A financing announcement, not new clinical evidence; Phase 3 is planned, not completed. Nothing here concerns Pelogen™ or Panacea Bio Chem.

Patent literature

[7]Patent literature2019

Compositions and methods for modulating hair growth (WO2019006359A1)

The Regents of the University of California (applicant) · WIPO patent publication WO2019006359A1, published 2019-01-03 · 2019

Original source ↗

What it supports
Patent literature describing compositions and methods for modulating hair growth via mitochondrial pyruvate carrier inhibition — the intellectual-property record around follicular metabolic modulation originating from the University of California.
What it does not show
A patent document describes claimed inventions; it is not clinical evidence and grants no proof of efficacy. It documents the University of California origin of the compound class — not Panacea Bio Chem.
[8]Patent literature2022

Compositions and methods for modulating hair growth (US20220048908A1)

The Regents of the University of California (applicant) · US patent application publication US20220048908A1, published 2022-02-17 · 2022

Original source ↗

What it supports
The United States member of the same patent family, reinforcing that PP405-class follicular metabolic modulators are third-party University of California-originated intellectual property.
What it does not show
A published application, not a granted finding of efficacy; no clinical content. Not Panacea Bio Chem intellectual property.

Nomenclature

[9]Clinical registry2026

Suvomipic — WHO Proposed International Nonproprietary Name (INN), List 135

World Health Organization INN Programme · WHO Drug Information, Vol. 40, No. 2 (2026), Proposed INN List 135 · 2026

Original source ↗

What it supports
International nomenclature record: in 2026 the WHO INN programme published the proposed name suvomipic for the mitochondrial pyruvate carrier inhibitor developed as PP405, fixing the compound’s class in the global naming system.
What it does not show
A proposed INN within the WHO objection period, not a final-list entry and not any form of regulatory evaluation or approval. A naming record only.

Independent reviews

[10]Peer-reviewed research2024

Local and systemic mechanisms that control the hair follicle stem cell niche

Zhang B, Chen T. · Nat Rev Mol Cell Biol, 25(2):87-100 · 2024

Original source ↗ · doi:10.1038/s41580-023-00662-3 · PMID 37903969

What it supports
Independent review of the local and systemic signals governing the hair-follicle stem-cell niche — third-party scholarly context, unconnected with the PP405 developer, for how dormancy and activation are regulated.
What it does not show
A narrative of niche biology; it does not evaluate PP405, any metabolic modulator in humans, or any formulation question.
Bogdan Dicoias, Founder and Laboratory Director of Panacea Bio Chem, originator of the Pelogen formulation-research platform

Bogdan DicoiasPanacea Bio Chem Ltd

THE FOUNDER

Developed within the Panacea Bio Chem research universe

Dormant biology is not absent biology. Pelogen™ was developed as a disciplined formulation-research platform for investigating how follicular metabolic pathways may be studied without confusing scientific potential with established clinical proof.

— Bogdan Dicoias — Founder and Laboratory Director — Panacea Bio Chem

THE RESEARCH UNIVERSE

Pelogen™ in the Panacea Bio Chem Research Universe

Pelogen™ is part of the Panacea Bio Chem research universe: the formulation-research programmes, platform technologies and scientific communications led by Bogdan Dicoias. The Pelogen™ platform concept and its formulation research are Panacea Bio Chem work; the compound class it studies is not — PP405 remains third-party science, credited as such throughout.

FAQ

Frequently Asked Questions About PP405 and Hair Regrowth

Short answers with the evidence boundary attached; the FAQPage structured data on this page mirrors this visible list exactly.

What is Pelogen™?

Pelogen™ — Follicular Reactivation Research Serum — is an independent Panacea Bio Chem topical formulation-research platform developed for the laboratory study of PP405, dormant hair follicles, follicular stem-cell metabolism and androgenetic alopecia. It is presented for laboratory and formulation research purposes only; it is not an approved medicine, medical device or consumer cosmetic product.

What is PP405?

PP405 (proposed INN: suvomipic) is an investigational topical small molecule — a mitochondrial pyruvate carrier inhibitor — originated at the University of California, Los Angeles and licensed and developed clinically by Pelage Pharmaceuticals. It is not a peptide, vitamin, hormone or cosmetic extract, and it is not an approved drug anywhere. Panacea Bio Chem is not the originator of PP405.

Is PP405 a peptide?

No. PP405 is an investigational topical small molecule. Peptides are chains of amino acids; PP405 is a low-molecular-weight chemical entity acting on the mitochondrial pyruvate carrier. It is also not a vitamin, a hormone, a cosmetic extract or an approved medicine.

How is PP405 being investigated for hair regrowth?

Third-party research investigates PP405 in the context of hair regrowth through its action on follicular stem-cell metabolism: published mouse research links mitochondrial pyruvate-carrier inhibition to hair-follicle stem-cell activation, and the developer has completed a 78-subject vehicle-controlled Phase 2a trial in androgenetic alopecia (NCT06393452) with Phase 3 announced from 2026. All human investigation to date is the developer’s — none of it is Pelogen™ research.

How may PP405 affect dormant hair follicles?

The proposed mechanism — a research model, not an established fact — is that inhibiting the mitochondrial pyruvate carrier shifts hair-follicle stem cells toward a lactate-producing metabolic state associated with activation, which may support a transition from dormancy toward an active hair-cycle state. Published research indicates this pathway operates in mice; whether it reactivates dormant human follicles requires further clinical validation and is under third-party study.

Does PP405 regrow terminal hair?

That has not been established. The developer’s Phase 2a announcement reports an exploratory signal — at week 8, 31% of treated men with a higher degree of hair loss showed a greater than 20% increase in hair density versus 0% on vehicle — as company-reported, not peer-reviewed data from a small subgroup at an early timepoint. It does not demonstrate durable terminal-hair regrowth, and larger controlled trials are still ahead. Nothing is claimed for Pelogen™.

What do early PP405 clinical trials report?

The only human data are company-reported: Pelage Pharmaceuticals states its 78-subject Phase 2a trial met its primary tolerability endpoint and secondary pharmacokinetic endpoint with no detectable systemic absorption of PP405 in blood, and reports the exploratory week-8 density signal described above. These are third-party, company-reported results awaiting peer-reviewed publication and Phase 3 evaluation — they are not Pelogen™ clinical trials and not independent confirmation.

Has PP405 been approved for hair loss?

No. PP405 is investigational and has not been approved for hair loss or any other indication in any jurisdiction. The developer’s own communications describe Phase 3 trials as planned from 2026.

Is PP405 available as an approved treatment?

No. There is no approved PP405 treatment. Any product presenting PP405 as an available therapy would be misrepresenting its status; PP405 remains an investigational compound under clinical development by Pelage Pharmaceuticals.

What is the proposed mechanism of PP405?

The proposed mechanism is metabolic: PP405 inhibits the mitochondrial pyruvate carrier in hair-follicle stem cells, diverting pyruvate away from mitochondrial oxidation and toward lactate production — a metabolic state that published mouse research associates with stem-cell activation and hair-cycle entry. It is a mechanistic hypothesis supported by animal and cellular evidence, with early third-party human research ongoing.

What is the mitochondrial pyruvate carrier?

The mitochondrial pyruvate carrier (MPC) is the protein complex that transports pyruvate from the cell’s cytosol into mitochondria, where it would otherwise be oxidised for energy. Blocking it changes how a cell handles pyruvate; in hair-follicle stem cells, published research links that shift to a lactate-rich, activation-prone metabolic state.

Is PP405 being researched for androgenetic alopecia?

Yes — by its developer. Androgenetic alopecia is the condition studied in the completed Phase 2a trial (NCT06393452) and is the stated target of the Phase 3 programme announced from 2026. The rationale is that pattern hair loss can leave follicles miniaturised and dormant rather than destroyed, making follicular stem-cell metabolism a research-worthy angle. All of this is third-party research.

Is Pelogen an approved treatment?

No. Pelogen™ is an investigational formulation-research platform presented exclusively for laboratory and formulation research. It holds no therapeutic approval and no consumer-use authorisation anywhere, and none is claimed.

Is Pelogen the same formulation used in PP405 clinical trials?

No. Pelogen™ is Panacea Bio Chem’s independent research vehicle. The Phase 2a trial used the developer’s own proprietary trial formulation; Pelogen™ is not that formulation, is not equivalent or bioequivalent to it, and no such equivalence is claimed or implied.

Has Pelogen itself undergone clinical trials?

No. No Pelogen-specific clinical trial has been performed or completed, and none is claimed. Every clinical statement on this site concerns third-party PP405 studies conducted and reported by Pelage Pharmaceuticals — never Pelogen™.

Is Pelogen affiliated with Pelage Pharmaceuticals?

No. Pelogen™ is an independent Panacea Bio Chem research platform. It is not affiliated with, sponsored by, licensed by or endorsed by Pelage Pharmaceuticals.

Does the website disclose the formulation?

No. The Pelogen™ composition is intentionally undisclosed: the site publishes no concentrations, percentages, ratios, ingredient lists, mixing sequences or manufacturing detail. The vehicle is described only at a high level — a proprietary, pH-controlled topical research vehicle incorporating a controlled solvent system, aqueous matrix, humectant phase, solubilisation system and polymer-supported scalp interface.

What does “research use only” / “laboratory research only” mean?

It means exactly what the three-line statement says: Pelogen™ is presented for laboratory and formulation research purposes only; it is not for human or veterinary use; and it is not an approved medicine, medical device or consumer cosmetic product. There is no purchase pathway, no dosing guidance and no self-treatment context of any kind.

Where does the scientific information come from?

From the source library on the homepage: peer-reviewed literature (via PubMed), the ClinicalTrials.gov registry record, the developer’s official announcements, patent publications and the WHO INN list — each entry labelled by evidence category and linked to the original source, with publication dates and the last scientific review date shown. Company-reported data are always labelled as such and are never merged with Pelogen™ formulation research.

How can a qualified research organisation contact Panacea Bio Chem?

Through the research enquiry section on the homepage (institutional details and the research-use acknowledgement are required) or via the Panacea Bio Chem contact page at panaceabiochem.com/contact/. Enquiries are handled as scientific correspondence; this platform cannot respond to treatment requests, dosing questions or consumer sales enquiries.

INSTITUTIONAL CONTACT

Research Enquiry

Pelogen™ welcomes serious institutional and scientific correspondence. There is no purchase pathway and no consumer order channel on this site; this platform cannot respond to treatment requests, dosing questions or sales enquiries. Qualified research organisations may also contact Panacea Bio Chem ↗.

RESEARCH USE ONLY

FOR LABORATORY AND FORMULATION RESEARCH PURPOSES ONLY.NOT FOR HUMAN OR VETERINARY USE.NOT AN APPROVED MEDICINE, MEDICAL DEVICE OR CONSUMER COSMETIC PRODUCT.

This platform carries no web form: enquiries travel as ordinary email and are handled as scientific correspondence. Write from your institutional address to contact@panaceabiochem.com, naming your organisation, your professional role, your country and your research interest, and stating that you acknowledge the research-use statement above.

SEND THE RESEARCH ENQUIRY BY EMAIL

Sending the enquiry acknowledges that Pelogen™ is presented exclusively for laboratory and formulation research and is not offered as an approved therapeutic or consumer-use product, and consents to Panacea Bio Chem Ltd processing the information you send for the purpose of responding to your enquiry, as described in the privacy notice.

Technical documentation is shared at Panacea Bio Chem’s discretion with qualified research organisations. Requesting documentation does not create any supply, evaluation or commercial relationship.

THE PANACEA TECHNOLOGY UNIVERSE

Twenty-four technologies, each the leader of its class

Proprietary Panacea Bio Chem Ltd technologies, invented by Bogdan Dicoias — what each one does, and why it leads its class.

  • Lyoprester® logo — Panacea Bio Chem technology by Bogdan Dicoias

    Lyoprester®

    The only dual-chamber cartridge that is autoreconstitution-enabled, vacuum-sealed and argon-fillback.

    Cake and liquid never meet until the moment of use — no contamination, no transfer, no compromise. A conventional vial wets only the surface; the Lyoprester carries Peptourbillon loads approaching 200 mg.

    Lyoprester SS: screw a needle, inject, throw.

    lyoprester.com

  • P-EARLs logo — Panacea Bio Chem technology by Bogdan Dicoias

    P-EARLs™

    Panacea-Engineered Aseptic Reconstitution Liquid(s) — each tuned to the peptide it wakes.

    Bacteriostatic water is a fine diluent and nothing more. A P-EARL is engineered around the peptide’s pI-aggregation behaviour and its Met/Cys/His/Trp oxidation profile.

    GHK-Cu: a chelation-withholding liquid design, not generic water.

    p-earls.com

  • Peptourbillon logo — Panacea Bio Chem technology by Bogdan Dicoias

    Peptourbillon™

    The layered peptide formulation architecture — single- or multi-layer, never a blend.

    Each active keeps its own lyophilised phase: near-eutectic layering, ultrasound freezing, −80 °C stack, RF-assisted drying. Chemistries that would destroy each other in a blend arrive as neighbours, not mixtures.

    Dual-layer cakes: one active below, a second above — one chamber, zero contact.

    peptourbillon.com

  • RF Tunnel logo — Panacea Bio Chem technology by Bogdan Dicoias

    RF Tunnel™

    The RF-formed central channel through the cake.

    Two wetting fronts instead of one — reconstitution solved by geometry, not surfactants.

    The hard cases: heavy-loaded, lipidated (GLP-class) and gel-blocking APIs.

    rftunnel.com

  • TgShift logo — Panacea Bio Chem technology by Bogdan Dicoias

    TgShift™

    Raises the cake’s glass-transition temperature with RF — instead of chilling below it.

    Drying runs warmer and faster while the structure stays below collapse — cycles shorten from days toward hours.

    Reference points: trehalose ≈ −29 °C, sucrose ≈ −32 °C — shifted upward, not endured.

    tgshift.com

  • Cryolapse logo — Panacea Bio Chem technology by Bogdan Dicoias

    Cryolapse™

    Cryogenic pressure collapse under S3Pulse™ control — vapour redistributed through the whole cake, not its surface, impeding crust formation.

    A collapse, not a yank: vapour redistributes gently through the whole lyocake instead of being driven off its surface, which impedes crust formation. Cryopumping to −110 °C, surfactant-free.

    A representative peptide cycle pulled from ~13 hours toward ~4, without a surfactant in sight.

    cryolapse.com

  • LyoLevit logo — Panacea Bio Chem technology by Bogdan Dicoias

    LyoLevit™

    The cake levitates and spins in high orbit — driven by ultrasound and RF.

    Company-reported zero-contact processing: 99% reproducibility, 89% energy reduction, a 4–6× gain in sublimation surface.

    No shelf contact means no hot spots — uniformity is the mechanism, not the hope.

    lyolevit.com

  • Lyochrysalis logo — Panacea Bio Chem technology by Bogdan Dicoias

    Lyochrysalis™

    The integrated chamber housing the whole drying stack.

    It finishes cold — it never cooks the peptide. No +40/+60 °C secondary bake, so binding affinity and bioavailability survive.

    TgShift + LyoLevit + Cryolapse + DiastolVAC + S3Pulse in one housing.

    lyochrysalis.com

  • S3Pulse logo — Panacea Bio Chem technology by Bogdan Dicoias

    S3Pulse™

    The control brain for every piece of Panacea hardware.

    Sixteen relay channels, three dipped product probes as the authority, Cryo-Triad event detection and a Kv-learning adaptive ramp — the only platform that enables every other technology.

    14,909 automated contract tests stand behind the control law.

    s3pulse.com

  • Liquiprester logo — Panacea Bio Chem technology by Bogdan Dicoias

    Liquiprester™

    The single-liquid cartridge engineered so multiple peptide APIs coexist in one shared vehicle.

    The glass may vary, the dose must not: a fixed plunger datum with ElimiVoid, bore-variance self-counterbalancing, and IncreSure verification per increment.

    Dose accuracy that survives manufacturing tolerance — by design, not inspection.

    liquiprester.com

  • Syntheseract logo — Panacea Bio Chem technology by Bogdan Dicoias

    Syntheseract™

    Continuous-flow peptide synthesis in a special, very fast and economical way.

    Batch synthesis is “more product, blindly”; Syntheseract is scalable production, observed — 64 positions, 128+ addresses, and a Digital Batch DNA for every run.

    Sprint, Economy and Fortress modes — the economics chosen per peptide, not per habit.

    syntheseract.com

  • CFSPPS logo — Panacea Bio Chem technology by Bogdan Dicoias

    CFSPPS™

    Continuous-flow solid-phase peptide synthesis, written as its own category.

    Setpoint ≠ experience: in flow, every residue addition is observed and repeatable instead of assumed.

    The category reference the field reads before arguing.

    cfspps.com

  • OxyDeplete logo — Panacea Bio Chem technology by Bogdan Dicoias

    OxyDeplete™

    Degassing plus no-headspace doctrine — the oxygen-starved seal.

    Trapped oxygen does not escape, it reacts. Remove it first and stability extends into years instead of months.

    Air seal vs oxygen-starved seal: the comparison the oxidation model is built on.

    oxydeplete.com

  • ArgonLock logo — Panacea Bio Chem technology by Bogdan Dicoias

    ArgonLock™

    The final inert-atmosphere lock under argon.

    After drying, the cake is backfilled and sealed under argon — the principle that protects welding arcs, wine cellars and the Charters of Freedom, applied to peptides.

    Air vs vacuum-only vs ArgonLock — the three-face comparison, settled.

    argonlock.com

  • RedoxVault logo — Panacea Bio Chem technology by Bogdan Dicoias

    RedoxVault™

    Separation, not merely suppression — redox isolation in lipid micro-reservoirs.

    A few ppb of iron can outweigh grams of antioxidant; the vault removes the catalyst from reach, with depot and delayed-release microsphere formats on top.

    A strongroom at the scale of a droplet — the ferritin principle, engineered.

    redoxvault.com

  • PleniDose logo — Panacea Bio Chem technology by Bogdan Dicoias

    PleniDose™

    The shared filling gantry — one machine filling both the dual-chamber Lyoprester and the liquid Liquiprester.

    Only the rods holder changes between the two product lines; the rear-plunger datum is fixed and pen-compatible. The glass may vary — the dose must not.

    Known inside the machine software as the Lyochrysalis Gantry: one gantry, two product lines.

    plenidose.com

  • IncreSure logo — Panacea Bio Chem technology by Bogdan Dicoias

    IncreSure™

    The dose-metrology layer — verified API per pen increment.

    The printed “60 IU” dial figure is not the API in the cartridge and not the volume per click. IncreSure characterises seven real pen parameters instead of trusting the label — a Cryolapse-enabled discipline.

    Piston travel per increment: measured, never assumed.

    incresure.com

  • ElimiVoid logo — Panacea Bio Chem technology by Bogdan Dicoias

    ElimiVoid™

    Front-void elimination without touching the metered dose.

    It removes the compressible air pocket ahead of the dose — without moving the rear plunger, without withdrawing API, without changing the delivered increment. A Cryolapse-enabled operation.

    The completion liquid is API-free, buffer-free and engineered to stay out of the way.

    elimivoid.com

  • Cryoviscous logo — Panacea Bio Chem technology by Bogdan Dicoias

    Cryoviscous™

    The characterised cold, high-viscosity, low-mobility conditioning state.

    The formulation is held temporarily still — strongly flow-restricted — for precision cartridge filling, then recovers within acceptance criteria on controlled warming.

    A processing state, not merely “cold liquid”.

    cryoviscous.com

  • Vana Machine logo — Panacea Bio Chem technology by Bogdan Dicoias

    Vana Machine™

    Vacuum Assisted Needle Accessory — vacuum conditioning and plunger-locking for the cartridge.

    It prevents air gaps and plunger drift, landing the target vacuum inside the Lyopresters and keeping it there until the moment of use.

    The machine that vacuum-conditions the cartridge before it ever meets a needle.

  • EZnject logo — Panacea Bio Chem technology by Bogdan Dicoias

    EZnject™

    The disposable auto-injector pen built around the Lyoprester.

    One twist activates autoreconstitution — the P-EARLs is drawn into the peptide chamber at the septa. A hundred indexed 0.1 mL doses with lab-grade accuracy; ships with 31G/5 mm needles and a Peptourbillon pre-loaded.

    One twist — no vial, no syringe, no transfer.

    panaceaeznject.com

  • Dicoias Ψ logo — Panacea Bio Chem technology by Bogdan Dicoias

    Dicoias Ψ

    The computed-chemistry advisory — every substance reduced to a vector across physical, electronic and formulation space.

    Structure-guided descriptors first, laboratory work second: the Ψ advisory ranks excipients, vehicles and layer candidates before the first bench run — the selection layer behind Panacea formulation decisions.

    The molecule’s structure reads the shortlist before the bench hears it.

    dcppsi.com

  • SealoPrester logo — Panacea Bio Chem technology by Bogdan Dicoias

    SealoPrester™

    Aseptic Cartridge Closure System — Seal o’ Precision + Sterility.

    It mechanically seals the caps of vacuum-charged, argon-locked cartridges that arrive held together by vacuum alone — one wrong move and the cartridge self-reconstitutes or loses its atmosphere. In cahoots with VANA, it gives birth to the Lyoprester.

    The machine that turns a banal dual-chamber cartridge into a Lyoprester.

    sealoprester.com

  • Peptidic Liquid logo — Panacea Bio Chem technology by Bogdan Dicoias

    Peptidic Liquid

    The peptide formulation in solution — the active plus its buffers, cryoprotectants, lyoprotectants and scaffolders.

    A peptide is only as good as the liquid it lives in: this is the formulation that decides whether a dose survives freezing, drying, storage and the journey back to solution. Designed with Dicoias Ψ.

    The liquid every Lyoprester is born from and every Liquiprester keeps.

    peptidicliquid.com

Follicular reactivation research, disciplined by evidence.

Dormant biology is a research question. Pelogen™ keeps it one.